316 related articles for article (PubMed ID: 29119409)
1. Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.
Drake PM; Rabuka D
BioDrugs; 2017 Dec; 31(6):521-531. PubMed ID: 29119409
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
4. Pushing the Envelope: Advancement of ADCs Outside of Oncology.
McPherson MJ; Hobson AD
Methods Mol Biol; 2020; 2078():23-36. PubMed ID: 31643047
[TBL] [Abstract][Full Text] [Related]
5. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
6. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
8. Developments in the use of antibody-drug conjugates.
Burris HA
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714468
[TBL] [Abstract][Full Text] [Related]
9. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.
Gerber HP; Koehn FE; Abraham RT
Nat Prod Rep; 2013 May; 30(5):625-39. PubMed ID: 23525375
[TBL] [Abstract][Full Text] [Related]
10. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
11. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
12. What makes a good antibody-drug conjugate?
De Cecco M; Galbraith DN; McDermott LL
Expert Opin Biol Ther; 2021 Jul; 21(7):841-847. PubMed ID: 33605810
[No Abstract] [Full Text] [Related]
13. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
16. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates come of age in oncology.
Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
[TBL] [Abstract][Full Text] [Related]
18. Challenges and advances in the assessment of the disposition of antibody-drug conjugates.
Kamath AV; Iyer S
Biopharm Drug Dispos; 2016 Mar; 37(2):66-74. PubMed ID: 25904406
[TBL] [Abstract][Full Text] [Related]
19. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
20. Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L; Sadilkova L; Viricel W; Dumontet C
J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
